Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial
…, ED Bateman, D O'Donnell, S Witte, D Bredenbröker… - The Lancet, 2005 - thelancet.com
Background Chronic obstructive pulmonary disease (COPD) is characterised by progressive
airflow limitation associated with chronic inflammation. There are few treatment options for …
airflow limitation associated with chronic inflammation. There are few treatment options for …
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
…, RM Verhoosel, PJ Sterk, JJ Hospers, D Bredenbröker… - Thorax, 2007 - thorax.bmj.com
Background: Roflumilast is a targeted oral once-daily administered phosphodiesterase 4 (PDE4)
inhibitor with clinical efficacy in chronic obstructive pulmonary disease (COPD). Results …
inhibitor with clinical efficacy in chronic obstructive pulmonary disease (COPD). Results …
[HTML][HTML] Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD
…, PMA Calverley, UM Goehring, D Bredenbröker… - Respiratory …, 2011 - Springer
Background As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease
it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, …
it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, …
Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history
…, M Brose, D Bredenbröker… - European …, 2011 - Eur Respiratory Soc
The oral, selective phosphodiesterase type-4 inhibitor roflumilast reduces exacerbations
and improves lung function in patients with severe-to-very severe chronic obstructive …
and improves lung function in patients with severe-to-very severe chronic obstructive …
Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus
EFM Wouters, D Bredenbröker… - The Journal of …, 2012 - academic.oup.com
Context: The phosphodiesterase 4 inhibitor roflumilast is a first-in-class antiinflammatory
treatment for severe chronic obstructive pulmonary disease (COPD) associated with chronic …
treatment for severe chronic obstructive pulmonary disease (COPD) associated with chronic …
Efficacy of roflumilast in the COPD frequent exacerbator phenotype
Background COPD exacerbations are associated with increased morbidity and mortality and
can accelerate disease progression. The best predictor of future exacerbations is a history …
can accelerate disease progression. The best predictor of future exacerbations is a history …
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD
…, PR Kowey, PMA Calverley, D Bredenbröker… - Chest, 2013 - Elsevier
Background Evaluation of cardiovascular safety for new therapies for COPD is important
because of a high prevalence of cardiac comorbidities in the COPD population. Hence, we …
because of a high prevalence of cardiac comorbidities in the COPD population. Hence, we …
[HTML][HTML] Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
…, T Strinich, RM Watson, D Bredenbröker… - Respiratory …, 2011 - Springer
Background Phosphodiesterase 4 (PDE4) inhibitors increase intracellular cyclic adenosine
monophosphate (cAMP), leading to regulation of inflammatory cell functions. Roflumilast is a …
monophosphate (cAMP), leading to regulation of inflammatory cell functions. Roflumilast is a …
Comparison of roflumilast, an oral anti‐inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma
…, U Harnest, B Kroemer, A Albrecht, D Bredenbröker - Allergy, 2006 - Wiley Online Library
Background: Roflumilast is an oral, once‐daily phosphodiesterase 4 inhibitor with anti‐inflammatory
activity in development for the treatment of asthma. Roflumilast was compared with …
activity in development for the treatment of asthma. Roflumilast was compared with …
Efficacy and safety of roflumilast in the treatment of asthma
…, C Schmid-Wirlitsch, S Leichtl, D Bredenbröker - Annals of Allergy …, 2006 - Elsevier
BACKGROUND: The central role of chronic inflammation of the airways in asthma pathogenesis
is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, …
is supported by the efficacy of corticosteroids in controlling clinical symptoms. However, …